Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H11Cl2N.ClH |
Molecular Weight | 264.579 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12C[C@@]1(CNC2)C3=CC(Cl)=C(Cl)C=C3
InChI
InChIKey=KAGBHVBIOJBGBD-IBYXRORRSA-N
InChI=1S/C11H11Cl2N.ClH/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11;/h1-3,8,14H,4-6H2;1H/t8-,11+;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16636898Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18539031 | https://www.ncbi.nlm.nih.gov/pubmed/17908267
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16636898
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18539031 | https://www.ncbi.nlm.nih.gov/pubmed/17908267
DOV-102,677 is a “Triple” Monoamine Neurotransmitter Uptake Inhibitor being developed by Merck for treating the major depressive disorder. In preclinical studies, DOV 102,677 increased extracellular levels of DA and 5-HT in the prefrontal cortex at 100 min after administration. DA levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. NE levels increased linearly to a maximum of 240 min post-dosing. Consistent with these increases in NE levels, the density of β-adrenoceptors was selectively decreased in the cortex of rats treated with DOV 102,677. DOV 102,677 dose-dependently reduced the amount of time spent immobile by rats in the forced swim test, a model predictive of antidepressant activity, with a minimum effective dose (MED) of 20 mg/kg and a maximal efficacy comparable to imipramine. However, phase I clinical trials for treatment Depression in the USA was discontinued. Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18539031 |
103.0 nM [IC50] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18539031 |
129.0 nM [IC50] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18539031 |
133.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1780 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22150508 |
20 mg/kg single, oral dose: 20 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
DOV-102677 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22150508 |
20 mg/kg single, oral dose: 20 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
DOV-102677 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16636898
Rat: 20 mg/kg per day, PO, 35 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16636898
HEK-hDAT and HEK-hSERT cells were incubated in modified Eagle’s medium supplemented with 5% fetal bovine serum, 5% calf bovine serum, 0.05 U penicillin/streptomycin and puromycin (2 μg/mL). HEK-hNET cells were incubated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 0.05 U penicillin/streptomycin and geneticin (300 μg/mL). Cells were grown until confluent on 150 mm diameter tissue culture dishes in a humidified 10% CO2 environment at 37◦C. [125I]RTI-55 (Perkin Elmer Life Sciences, Boston, MA) was used in competition binding assays characterizing DOV 102,677 affinity for the three monoamine neurotransmitter transporters. Aliquots (50 μL) of the suspended cells were added to assay tubes containing drugs and Krebs-HEPES assay buffer in a final assay volume of 0.5 mL. Uptake inhibition studies were conducted using triplicate determinations for each test substance. [3H]DA, [3H]5-HT, or [3H]NE (Perkin Elmer Life Sciences, Boston, MA, 56, 26.9, 60 Ci/mmol, respectively, 20 nM final concentration) was added after a 10 min pre-incubation of the isolated cells in a 25◦C water bath, and the assay incubated an additional 10 min. The reaction was terminated by vacuum filtration over Whatman GF/C filters using a 96-well Tomtec cell harvester (Hamden, CT). Specific uptake was defined as the difference in uptake observed in the absence and presence of 5 μM mazindol (hDAT and hNET) or 5 μM imipramine (hSERT).
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
500733-69-7
Created by
admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
|
PRIMARY | |||
|
16072154
Created by
admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
|
PRIMARY | |||
|
8WR4Q5ZGU3
Created by
admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD